Advertisement
Research Article| Volume 9, ISSUE 1, P29-33, March 1999

Mifepristone and misoprostol

  • P.C. Ho
    Correspondence
    Correspondence to: P.C.H.
    Affiliations
    Department of Obstetrics & Gynaecology, The University of Hong Kong, 6/F, Professional block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
    Search for articles by this author
  • S.W. Ngai
    Affiliations
    Department of Obstetrics & Gynaecology, The University of Hong Kong, 6/F, Professional block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China
    Search for articles by this author
DOI:https://doi.org/10.1016/S0957-5847(99)90070-7
Mifepristone and misoprostol
Previous ArticleGestational diabetes
Next ArticleCommunication between doctors and patients
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Obstetrics, Gynaecology and Reproductive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Cadepond F.
        • Ulmann A.
        • Baulieu E.E.
        RU486 (mifepristone): mechanisms of action and clinical uses.
        Annu Rev Med. 1997; 48: 129-156
        • Lahteenmaki P.
        • Heikinheimo O.
        • Croxatto H.
        • et al.
        Pharmacokinetics and metabolism of RU486.
        J Steroid Biochem. 1987; 27: 859-863
        • Norman J.E.
        • Thong K.J.
        • Baird D.T.
        Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone.
        Lancet. 1991; 338: 1233-1237
        • Zieman M.
        • Fong S.K.
        • Benowitz N.L.
        • et al.
        Absorption kinetics of misoprostol with oral or vaginal administration.
        Obstet Gynecol. 1997; 90: 88-91
        • Tang G.W.K.
        • Lau O.W.K.
        • Yip P.
        Further acceptability evaluation of RU486 and ONO 802 as abortifacient agents in a Chinese population.
        Contraception. 1993; 48: 267-276
        • Couzinet B.
        • Strat N.L.
        • Ulmann A.
        • et al.
        Termination of early pregnancy by the progesterone antagonist RU486 (mifepristone).
        N Engl J Med. 1986; 315: 1565-1570
        • Bygdeman M.
        • Swahn M.L.
        Progesterone receptor blockage. Effect of uterine contractility and early pregnancy.
        Contraception. 1985; 32: 45-51
        • Silvestre L.
        • Dubois C.
        • Renault M.
        • et al.
        Voluntary interruption of pregnancy with mifepristone (RU486) and a prostaglandin analogue.
        N Engl J Med. 1990; 322: 645-648
        • Urquhart D.R.
        • Templeton A.A.
        • Shinewi F.
        • et al.
        The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicentre study-final results.
        Contraception. 1997; 55: 1-5
        • World Health Organization
        Termination of pregnancy with reduced doses of mifepristone.
        Br Med J. 1993; 307: 532-537
        • Baird D.T.
        • Sukcharoen N.
        • Thong K.J.
        Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
        Hum Reprod. 1995; 10: 1521-1527
        • El-Refaey H.
        • Rajasekar D.
        • Abdalla M.
        • et al.
        Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
        N Engl J Med. 1995; 332: 983-987
        • Koopersmith T.B.
        • Mishell Jr., D.R.
        The use of misoprostol for termination of early pregnancy.
        Contraception. 1996; 53: 237-242
        • Bugalho A.
        • Faundes A.
        • Jamisse L.
        • et al.
        Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion.
        Contraception. 1996; 53: 243-246
        • Carbonell J.L.L.
        • Varela L.
        • Velazco A.
        • et al.
        The use of misoprostol for termination of early pregnancy.
        Contraception. 1997; 55: 165-168
        • Creinin M.D.
        • Darney P.H.
        Methotrexate and misoprostol for early abortion.
        Contraception. 1993; 48: 339-348
        • Creinin M.D.
        Oral methotrexate and vaginal misoprostol for early abortion.
        Contraception. 1996; 54: 15-18
        • Ho P.C.
        • Ma H.K.
        Termination of pregnancy with sulprostone and mifepristone: a randomized double-blind placebo-controlled trial.
        Contraception. 1993; 47: 123-129
        • Ho P.C.
        • Tsang S.S.K.
        • Ma H.K.
        Reducing the induction-to-abortion interval in termination of second trimester pregnancies: a comparison of mifepristone with laminaria tent.
        Br J Obstet Gynaecol. 1995; 102: 651-684
        • Ho P.C.
        • Chan Y.F.
        • Lau W.
        Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomized comparative trial.
        Contraception. 1996; 53: 281-283
        • Ho P.C.
        • Ngai S.W.
        • Liu K.L.
        • et al.
        Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy.
        Obstet Gynecol. 1997; 90: 735-738
        • Jain J.K.
        • Mishell R.
        A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy.
        The New Engl J Med. 1994; 331: 290-293
        • Wong K.S.
        • Ngai C.S.W.
        • Wong A.Y.K.
        • et al.
        Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomized trial.
        Contraception. 1998; 58: 207-210
        • Ho P.C.
        Termination of pregnancy between 9 and 14 weeks.
        in: Baird D.T. Grimes D.A. van Look P.F.A. Modern methods of inducing abortion. Blackwell Science, 1995: 54-69
        • World Health Organization Task Force on Prostaglandins for Fertility Regulation
        Vaginal administration of 15-methyl-PGF2α methyl ester for pre-operative cervical dilatation.
        Contraception. 1981; 23: 251-257
        • World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation
        The use of mifepristone (RU486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration.
        Br J Obstet Gynaecol. 1990; 97: 260-266
        • El-Refaey H.
        • Calder L.
        • Wheatley D.N.
        • et al.
        Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost.
        Lancet. 1994; 343: 1207-1209
        • Ngai S.W.
        • Au Yeung K.C.
        • Lao T.
        • et al.
        Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation.
        Contraception. 1995; 51: 347-350
        • Henshaw R.C.
        • Templeton A.A.
        Pre-operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU486).
        Br J Obstet Gynaecol. 1991; 98: 1025-1030
        • Ngai S.W.
        • Au Yeung K.C.
        • Lao T.
        • et al.
        Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomized study.
        Br J Obstet Gynaecol. 1996; 103: 1120-1123
        • Lawrie A.
        • Penney G.
        • Templeton A.
        A randomized comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy.
        Br J Obstet Gynaecol. 1996; 103: 1117-1119
        • Ngai S.W.
        • Chan Y.M.
        • Liu K.L.
        • et al.
        Oral misoprostol for cervical priming in non-pregnant women.
        Human Reprod. 1997; 12: 2373-2375
        • Refaey H.E.
        • Hinshaw K.
        • Henshaw
        • et al.
        Medical management of missed abortion and anembryonic pregnancy.
        Br Med J. 1992; 305: 1399
        • Chung T.K.H.
        • Cheung L.P.
        • Leung T.Y.
        • et al.
        Misoprostol in the management of spontaneous abortion.
        Br J Obstet Gynaecol. 1995; 102: 832-835
        • Creinin M.D.
        • Moyer R.
        • Guido R.
        Misoprostol for medical evacuation of early pregnancy failure.
        Obstet Gynecol. 1997; 89 (5 part 1): 768-772
        • Frydman R.
        • Lelaidier C.
        • Baton-Saint-Mleux C.
        • et al.
        Labor induction in women at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study.
        Obstet Gynecol. 1992; 80: 972-975
        • Margulies M.
        • Campos-Pertez G.
        • Voto L.S.
        Misoprostol to induce labor.
        Lancet. 1992; 339 ([letter]): 64
        • Ngai S.W.
        • To W.K.
        • Lao T.
        • et al.
        Cervical priming with oral misoprostol in pre-labor rupture of membranes at term.
        Obstet Gynecol. 1996; 87: 923-927
        • Sanchez-Ramos L.
        • Kaunitz A.M.
        • Wears R.
        • et al.
        Misoprostol for cervical ripening and labor induction.
        Obstet Gynecol. 1997; 89: 633-642
        • Glasier A.K.
        • Thong J.
        • Dewar
        • et al.
        Mifepristone (RU486) compared with high-dose estrogen and progesterone for emergency postcoital contraception.
        N Engl J Med. 1992; 327: 1041-1044
        • Webb A.M.C.
        • Russel J.
        • Elstein M.
        Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception.
        Br Med J. 1992; 305: 927-931
        • World Health Organization
        Antiprogestogen-only emergency contraception (mifepristone).
        Annual Technical Report. 1996; : 46-47
        • Royal College of Obstetricians and Gynaecologists
        Induced Abortion. Guideline No. 11. July 1997

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0957-5847(99)90070-7

      Copyright

      © 1999 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX